Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review
Open Access
- 27 March 2024
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 16 (3) , e57066
Abstract
Guillain-Barré syndrome (GBS) is a rare and debilitating autoimmune disorder that affects the peripheral nervous system. Although the exact etiology of GBS is still unknown, it is thought to be triggered by a preceding gastrointestinal infection in most of the cases. Clinical manifestations include limb weakness, areflexia, and sensory loss that can further progress to neuromuscular paralysis affecting the respiratory, facial, and bulbar functions. Both plasmapheresis (PE) and intravenous immunoglobulin (IVIG) have shown effectiveness in the treatment of GBS, but it is still unclear which treatment approach is superior in terms of therapeutic efficacy. This systematic review acts per Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020 guidelines. For appropriate studies and research, we searched PubMed, PubMed Central (PMC), Medical Literature Analysis and Retrieval System Online (MEDLINE), Science Direct, and Google Scholar. Screening of articles was performed based on relevance and inclusion and exclusion criteria. To check for bias, we used relevant quality appraisal tools. Initially, we found 2454 articles. After removing duplicates and irrelevant papers, we finalized 31 studies based on titles, abstracts, and reading entire articles. We excluded 14 studies because of poor quality; the remaining 17 papers were included in this review. IVIG is equally efficacious as PE in improving primary outcomes and secondary outcomes. IVIG showed a slight advantage over PE in reducing the need for mechanical ventilation (MV) and hospital stay duration. However, in children, PE demonstrated a slight edge in improving secondary outcomes. PE was associated with a slightly higher risk of adverse events and post-treatment worsening symptoms compared to IVIG. IVIG is considered more user-friendly with a significantly lower patient discontinuation rate than PE. IVIG treatment was found to be significantly more expensive than PE.Keywords
This publication has 34 references indexed in Scilit:
- Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysiseNeurologicalSci, 2023
- Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain‐Barré syndromeMuscle & Nerve, 2020
- Intravenous immunoglobulin for Guillain-Barré syndromeCochrane Database of Systematic Reviews, 2014
- Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosisNature Reviews Neurology, 2014
- IVIG Treatment and Prognosis in Guillain–Barré SyndromeJournal of Clinical Immunology, 2010
- Clinical features, pathogenesis, and treatment of Guillain-Barré syndromeThe Lancet Neurology, 2008
- Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndromeThe Lancet, 1997
- High dose intravenous immune globulins and plasma exchange in Guillain-Barré SyndromeThe Italian Journal of Neurological Sciences, 1995
- Assessment of current diagnostic criteria for Guillain-Barr syndromeAnnals of Neurology, 1990
- CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHYThe Lancet, 1978